TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05504759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: splint
Description: Resting is the first step of treatment in lateral epicondylitis. Patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: splint
Description: Resting is the first step of treatment in lateral epicondylitis. Patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: splint
Description: Resting is the first step of treatment in lateral epicondylitis. Patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
Study: NCT05987345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEF
Description: PEF device treated in the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Anti-PD-1 monoclonal antibody administered on Day 7 then routinely.
Study: NCT05504759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: steroid
Description: Betamethasone Dipropionate + Betamethasone Sodium Phosphate-1 ml will be administered once at the beginning of the study to patients who will receive steroid injection, one of the local injection treatments. Steroid injection will be applied to the most sensitive point on the lateral epicondyle. Afterwards, patients will be given a 2 weeks rest protocol (works that may cause strain on the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during daytime hours for 2 weeks). The goal of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. Home exercises during the treatment of lateral epicondylitis will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: The needle will be guided to painful trigger points detected by palpation. Stainless steel 25x30 mm needles will be used for dry needling. Dry needle treatment will be applied to the painful trigger points in the forearm extensor group muscles with the stick-pull technique, 1 session per week, for a total of 2 sessions. Afterwards, the patients will be given a 2 weeks rest protocol (works that may strain the wrist and increase elbow pain will be described and it will be advised to stay away, and a home exercise program will be prepared, which includes the use of a resting splint during the daytime for 2 weeks). The purpose of exercise therapy will be to stretch the muscles, strengthen them and maintain flexibility. During the treatment of lateral epicondylitis, home exercises will be beneficial when performed twice a day for at least three months, and stretching exercises will be performed first, and then strengthening exercises will be started in a controlled manner.
Study: NCT05415345

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cecolin
Description: Bivalent HPV Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cecolin
Description: Bivalent HPV Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hecolin
Description: Hepatitis E vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hecolin
Description: Hepatitis E vaccine
Study: NCT05510518

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test (OGTT)
Description: • The OGTT involves assessing fasting blood glucose, drinking a solution comprising 100 g of glucose, and three glucose tests at one, two, and three hours following glucose load.
Study: NCT05314361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1-Day Cognitive Behavioural Therapy-Based Workshop
Description: The Online Workshop is a day-long intervention delivered by two trained public health nurses consisting of 6 hours of instruction delivered in 4 modules. The 1st contains information on PPD etiology with a focus on modifiable cognitive risk factors (e.g., negative thoughts, maladaptive core beliefs). The 2nd module focuses on cognitive skills including cognitive restructuring. The 3rd builds behavioural skills such as problem solving, behavioural activation, assertiveness, sleep strategies, and using supports. The final module provides an opportunity for goal setting/action planning. Teaching methods include didactic sections, group exercises, and role-plays. Regular breaks are incorporated. Each participant is given a professionally designed manual to facilitate learning. We also provide a list of region-specific PPD resources and a copy of the Canadian Practice Guidelines for the treatment of PPD (written by the NPA).
Study: NCT06211699

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Omentopexy with Laparoscopic Sleeve Gastrectomy
Description: Patients with omentum sewed to the remnant gastric staple line during laparoscopic sleeve gastrectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clips with Laparoscopic Sleeve Gastrectomy
Description: Patients performed clips to the remnant gastric staple line during laparoscopic sleeve gastrectomy
Study: NCT05211180

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vida Sana
Description: Weekly group or individual education sessions with a health coach and fitness tracking with a fitbit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vida Sana y Completa
Description: Weekly group or individual education sessions with a health coach, fitness tracking with a fitbit, and weekly food box delivery.
Study: NCT05013554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443216 IV
Description: Pharmaceutical form: Powder for solution; Route of administration: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443216 IV
Description: Pharmaceutical form: Powder for solution; Route of administration: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443216 IV
Description: Pharmaceutical form: Powder for solution; Route of administration: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443216 IV
Description: Pharmaceutical form: Powder for solution; Route of administration: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443216 IV
Description: Pharmaceutical form: Powder for solution; Route of administration: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443216 SC
Description: Pharmaceutical form: Powder for solution; Route of administration: SC injection
Study: NCT06362460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] RAY1216
Description: 400 mg suspension containing 100μCi of \[14C\]RAY1216
Study: NCT05879627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8007 for injection
Description: Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8007 for injection
Description: Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8007 for injection
Description: Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8007 for injection
Description: Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8007 for injection
Description: Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8007 for injection
Description: Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8007 for injection
Description: Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8007 for injection
Description: Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~120 minutes.
Study: NCT05389059

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CAF+CM
Description: Periodontal surgery including CAF+CM application

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CAF+CM
Description: Periodontal surgery including CAF+CM application

Intervention type: PROCEDURE
Group type: OTHER
Intervention: I-PRF
Description: Periodontal surgery including CAF+CM application with i-PRF
Study: NCT05010629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-ING-41
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion
Study: NCT05978687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPHTESIC LIDOCAINE HYDROCHLORIDE 20MG/G
Description: In group A, all patients will receive topical 2% lidocaine gel (ophtesic lidocaine hydrochloride 20 mg/G) prior to surgery.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xylocaine with Epinephrine
Description: In group B, all patients will receive a subconjunctival injection with xylocaine 2% hydrochloride solution with 0.125 epinephrine will be injected with a 27-gauge needle. When asked for, patients will receive additional topical 1% lidocaine eye drops.~Operative technique A traction suture is applied at the superior limbus (Vicryl 6.0) with a Kocher. The head of the pterygium is separated from its body with scissors. Afterwards it is removed by blunt dissection. The subconjunctival tissue under the body of the lesion is removed. The conjunctival graft is separated from the Tenon's capsule for harvest by ballooning with SBSS in group A and by injection with 0.5 mL of 2% xylocaine in group B. The autograft is excised from the superior temporal side. Hereafter, the graft is secured to the recipient bed with sutures. The traction suture is removed. All operations are executed by the same surgeon.
Study: NCT04526119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acotiamide hydrochloride hydrate
Description: A white film-coated tablet containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase Administered orally, one tablet a time and three times a day before meals for 28 days in the open-label phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A white film-coated tablet not containing 100 mg Z-338 Administered orally, one tablet a time and three times a day before meals for 28 days in the double-blind phase
Study: NCT05940597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse field ablation
Description: ablation of paroxysmal atrial fibrillation by Pulse field ablation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoballoon pulmonary vein isolation
Description: ablation of paroxysmal atrial fibrillation by Cryoballoon pulmonary vein isolation
Study: NCT04721977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Tucatinib 300 mg administered BID via oral tablet

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 8 mg/kg loading dose followed by 6 mg/kg maintenance dose, administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2 administered BID via oral tablet
Study: NCT05902429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine 10 mg oral tablet
Description: Cladribine tablets (Mavenclad®, Merck KGaA, Darmstadt, Germany) will be given according to the label with a cumulative dose of 3.5 mg/kg body weight distributed over 2 years as one treatment course of 1.75 mg/kg per year. Each treatment course will consist of 2 weeks of treatment, one at the beginning of the first month and one at the beginning of the second month of the respective year of treatment. Each treatment week will consist of 4 or 5 days in which the participant will receive 10 mg or 20 mg (1 or 2 tablets, respectively) as a single daily dose, depending on body weight, according to the tables available in label. Upon completion of the two treatment courses, no further courses will be required in years 3 and 4.
Study: NCT04793035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Omega-Cuff
Description: An omega-shaped nitinol device to be placed and secured on the Lower Esophageal Sphincter area
Study: NCT04918303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SKNA recording
Description: The coupled recording of the sympathetic nervous activity of the skin and of an ECG will be carried out using the ME6000 device, CE marked, from the Bittium company.~It will be performed for a maximum period of one hour at Day 1, Post-procedure between Day 1 and discharge from hospital, and month 6
Study: NCT04039386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cell Phone Based Cognitive Based Therapy (Pacifica App)
Description: Cell phone application that provides support for individuals with psychosocial conditions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Subjects in the control group will receive standard care.
Study: NCT05089474

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Streamline Surgical System
Description: The Streamline System is a device that delivers viscoelastic into Schlemm's Canal.
Study: NCT04874675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac / acetaminophen /codeine
Description: routine pain medication used post extraction of third molars

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibuprofen/acetaminophen/codeine
Description: routine pain medication used post extraction of third molars
Study: NCT05986331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-201
Description: up to 8 treatment cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keytruda
Description: up to 8 treatment cycles
Study: NCT06464432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Skills Training in Affective and Interpersonal Regulation
Description: Enhanced Skills Training in Affective and Interpersonal Regulation combined with Modified Prolonged Exposure (ESTAIR); Psychotherapeutic manual for the treatment of Complex Post-Traumatic Stress Disorder (CPTSD) consisting of 4 therapeutic modules: 1. Emotion Regulation, 2, Self-concept, 3. Relationship Patterns, 4. Prolonged Exposure.
Study: NCT06010862

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA CAR-T cells
Description: After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were transfused intravenically

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CEA CAR-T cells
Description: After lymphodepletion with Fludarabine and Cyclophosphamide,CAR T cells were injected intraperitoneally
Study: NCT05650931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of PNS electrodes during surgery, mapping to select sites with the best effect and pain modulation.
Description: PNS electrodes are implanted in the area of peripheral nerves of the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate peripheral nerves at different sites in the stump. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCS electrode implantation at surgery, mapping to select sites with the best effect and pain modulation.
Description: SNS electrodes are implanted in the area of targeted peripheral nerves in the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate the spinal cord at different sites in the cervical thickening (C5-T1). Stimulation starts at a specific site at a frequency of 1 Hz and increases by 0.1 Hz until the patient no longer feels phantom pain. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG to search for phantom pain biomarkers
Description: This procedure uses the method of electroencephalography (EEG). EEG signals are recorded during the entire experiment. First, the patient is recorded at rest with stimulator on (PNS/SCS) with eyes open and then closed, in the stimulator off state (eyes open, then closed) when patient's pain returns to its preoperative state. The stimulation is then turned back on to the original level of pain suppression. The moments of pain suppression are fixed by marking.
Study: NCT04962503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: Six adult patients with clots located in the higher segments of the brain and who are ineligible for alternative treatments will be enrolled in the study and evaluated for six weeks. The study will assess patients' brain injury with computed tomography (CT) scans and magnetic resonance imaging (MRI), as well as using recognised methods of clinical evaluation to measure changes in patients' neurological and cognitive function following treatment.
Study: NCT04605731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT06501911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Patients will receive daily oral bicalutamide for six (6) months. The dose will be determined by the cohort to which the participant is enrolled as well as the toxicities experienced by previously enrolled cohorts.
Study: NCT06280248

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic ultrasound guided cystogastrostomy of symptomatic pancreatic pseudocyst
Description: The technical success rates, clinical success rates, and potential complications of the different endoscopic ultrasound-guided techniques for the best drainage of pancreatic fluid collections (PFCs) as regard type, caliber, and number of plastic stents and the ideal timing for stent removal will be assessed.~Also compare early vs. late intervention for complete endoscopic necrosectomy of walled off pancreatic necrosis (WOPN ) as regard to technical success rates, clinical success rates, potential complications, and the number of sessions needed will be done.~In order to evaluate total resolution or a reduction in cyst diameters with clinically significant improvement in symptoms, patients will be monitored for one month and six months following the insertion of the stent.
Study: NCT06467682

Intervention type: OTHER
Group type: OTHER
Intervention: tele-exercise
Description: The 12-week tele-exercise program will be performed and supported via the USTEP digital platform, with each patient taking part in 3 training sessions per week with a 60-min duration period per training session. There will be personalized training sessions: i) warm-up and warm-down, ii) aerobic exercise, and iii) strength exercises. All tele-exercise program participants, will use wearable-based tracking to assessment the cardio-oxygenation.
Study: NCT06487871

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fucoidan extracted from Undaria pinnatifida (UPF)
Description: Two capsules to be taken after breakfast daily, with 200 ml glass of water for 90 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules to be taken after breakfast daily, with 200 ml glass of water for 90 days.
Study: NCT04765696

Intervention type: OTHER
Intervention: No intervention is administered
Description: No intervention is administered, the cohort is followed in order to evaluate the impact of housing and relocation on active ageing outcomes.